Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

Seres Therapeutics (MCRB) EBIT Margin (2016 - 2025)

Seres Therapeutics (MCRB) has disclosed EBIT Margin for 9 consecutive years, with 4423.97% as the latest value for Q4 2025.

  • Quarterly EBIT Margin changed N/A to 4423.97% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 11910.14% through Dec 2025, changed N/A year-over-year, with the annual reading at 11910.14% for FY2025, N/A changed from the prior year.
  • EBIT Margin hit 4423.97% in Q4 2025 for Seres Therapeutics, up from 6403.7% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 53.98% in Q3 2021 to a low of 14382.58% in Q3 2023.
  • Historically, EBIT Margin has averaged 3700.1% across 4 years, with a median of 1315.48% in 2022.
  • Biggest YoY gain for EBIT Margin was 524681bps in 2023; the steepest drop was -1266635bps in 2023.
  • Year by year, EBIT Margin stood at 684.56% in 2021, then surged by 74bps to 177.54% in 2022, then surged by 117bps to 29.32% in 2023, then plummeted by -15187bps to 4423.97% in 2025.
  • Business Quant data shows EBIT Margin for MCRB at 4423.97% in Q4 2025, 6403.7% in Q3 2025, and 29.32% in Q4 2023.